Literature DB >> 2965002

Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS.

P A Arnold1, B J Guglielmo, H Hollander.   

Abstract

A patient with acquired immunodeficiency syndrome (AIDS) developed rash, fever, neutropenia, and elevated liver function tests during an initial course of trimethoprim-sulfamethoxazole (TMP-SMX) therapy. Upon reexposure to the drug, the patient experienced a severe anaphylactoid reaction associated with pulmonary edema and rhabdomyolysis. Reactions associated with TMP-SMX rechallenge in this patient population have been previously reported but have not been associated with this degree of severity. TMP-SMX therapy should be instituted with extreme caution in patients with AIDS who have demonstrated a prior hypersensitivity reaction to the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965002     DOI: 10.1177/106002808802200110

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity.

Authors:  Mirella Jane Parsonage; Gavin Barlow; Patrick Lillie; Peter Moss; Katherine Adams; Hiten Thaker
Journal:  BMJ Case Rep       Date:  2009-06-15

Review 2.  Role of desensitisation for drug hypersensitivity in patients with HIV infection.

Authors:  A Carr
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

3.  Allergic manifestations of human immunodeficiency virus (HIV) infection.

Authors:  A Carr; D A Cooper; R Penny
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

Review 4.  Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature.

Authors:  Toshihiko Komai; Shuji Sumitomo; Shuzo Teruya; Keishi Fujio
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.